Dataset Information


Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status.

ABSTRACT: Background/Aims:Antiviral therapy (AVT) reduces the risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB). This multicenter retrospective study investigated the effects of AVT and hepatitis B virus (HBV)-related factors on the risk of HCC development in a cohort with heterogeneous HBV status. Methods:A total of 1,843 patients with CHB from two institutions were included in this study. Ultrasound and laboratory tests, including the ?-fetoprotein test, were conducted regularly to detect HCC development. Results:The mean age of our study population (1,063 men and 780 women) was 49.4 years. Cirrhosis was identified in 617 patients (33.5%). During follow-up (median, 42.5 months), 81 patients developed HCC (1.39% per person-year). A total of 645 patients (35.0%) received ongoing AVT at enrollment. Ongoing AVT was not significantly associated with the risk of HCC development (all p>0.05). HBV-related variables (HBV DNA level, hepatitis B e antigen status, and alanine aminotransferase level) were also not significantly associated with the risk of HCC development (all p>0.05). In contrast, cirrhosis was significantly associated with the risk of HCC development, regardless of adjustment (adjusted hazard ratio=4.098 to 7.020; all p<0.05). Cirrhosis significantly predicted the risk of HCC development in subgroups with and without ongoing AVT at enrollment, regardless of adjustment. Conclusions:Our study showed that cirrhosis, not AVT and HBV-related variables, was associated with HCC development in a cohort of patients with heterogeneous HBV status. Our results may help clinicians apply individualized surveillance strategies according to fibrotic status in patients with CHB.


PROVIDER: S-EPMC6430437 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5055862 | BioStudies
2014-01-01 | S-EPMC4234899 | BioStudies
2020-01-01 | S-EPMC7706297 | BioStudies
2019-10-28 | GSE114783 | GEO
2019-01-01 | S-EPMC6821693 | BioStudies
2012-01-01 | S-EPMC3250489 | BioStudies
2017-01-01 | S-EPMC5732244 | BioStudies
2020-01-01 | S-EPMC7037346 | BioStudies
1000-01-01 | S-EPMC5309878 | BioStudies
2015-01-01 | S-EPMC4397430 | BioStudies